Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK

被引：2
|
作者：
Dodkins, J. [1 ]
Cook, A. [1 ]
Nossiter, J. [1 ]
Payne, H. A. [2 ]
Clarke, N. W. [3 ]
van der Meulen, J. [4 ]
Aggarwal, A. [4 ]
机构：
[1] Royal Coll Surgeons England, Clin Effectiveness Unit, London, England
[2] Univ Coll London Hosp NHS Fdn Trust, Dept Oncol, London, England
[3] Christie & Salford Royal NHS Fdn Trusts, Dept Urol, Manchester, Lancs, England
[4] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1790P
引用
收藏
页码：S967 / S967
页数：1
相关论文
共 50 条
  • [1] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Schwentner, Christian
    AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
  • [2] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Weiner, Adam B.
    Nettey, Oluwarotimi S.
    Morgans, Alicia K.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (09)
  • [3] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [4] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Adam B. Weiner
    Oluwarotimi S. Nettey
    Alicia K. Morgans
    Current Treatment Options in Oncology, 2019, 20
  • [5] Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
    Wala, Jeremiah
    Nguyen, Paul
    Pomerantz, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (20) : 3584 - +
  • [6] SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
    Omrcen, Tomislav
    ACTA CLINICA CROATICA, 2022, 61 : 81 - 85
  • [7] Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).
    Albiges, Laurence
    Xie, Wanling
    Chen, Yu-Hui
    Boher, Jean-Marie
    Valenca, Loana Bueno
    Bernard, Brandon David
    Culine, Stephane
    Habibian, Muriel
    Carducci, Michael Anthony
    DiPaola, Robert S.
    Liu, Glenn
    Pomerantz, Mark
    Nakabayashi, Mari
    Kantoff, Philip W.
    Fizazi, Karim
    Gravis, Gwenaelle
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
  • [9] DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA
    Yu, M.
    Duan, X.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    VALUE IN HEALTH, 2021, 24 : S39 - S40
  • [10] Utilization of metastatic hormone sensitive prostate cancer (mHSPC) treatment in a community oncology practice setting.
    Conner, Terri
    Appukkuttan, Sreevalsa
    Kong, Sheldon
    Jhaveri, Jay
    Ko, Gilbert
    Kalayeh, Bashir
    He, LiHong
    Hauser, Robert Sean
    Loaiza-Bonilla, Arturo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345